CC
RVMD icon

Commodore Capital’s Revolution Medicines RVMD Stock Holding History

Commodore Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-226,228
Closed -$6.22M – 30
2021
Q3 		$6.22M Buy
+226,228
New +$6.58M 1.64% 20

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Commodore Capital's RVMD Position: Q4 2021 in Review

Commodore Capital sold out of Revolution Medicines (RVMD) in Q4 2021, closing a stake of 226,228 shares — an estimated $6.22M sold.

Commodore Capital first reported a position in RVMD in Q3 2021 and held it in 1 quarter. The position peaked at $6.22M in Q3 2021. 117 funds tracked by Wall St. Rank hold RVMD as of Q4 2021.

  • Commodore Capital reported no remaining Revolution Medicines position as of Q4 2021 after selling out during the quarter.
  • Commodore Capital sold 226,228 Revolution Medicines shares in Q4 2021, an estimated $6.22M.
  • Commodore Capital first reported a position in Revolution Medicines in Q3 2021 and held it in 1 quarter.
  • Commodore Capital's Revolution Medicines position peaked at $6.22M in Q3 2021.
  • 117 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2021.

Based on Commodore Capital's 13F filing for Q4 2021, filed 14 Feb 2022.